Court-appointed receivers of investment firm Keystone have won an extension to a freezing order against a Melbourne developer who is suspected of receiving $160 million in investor funds.
Big Four bank ANZ and superannuation trustee OnePath will pay $50 million to settle a class action brought on behalf of super members allegedly charged excessive fees.
A judge should be disqualified from hearing a class action against Fletcher Building because of his previous association with the funder, as well as public remarks he made as a plaintiffs’ solicitor, a court has heard.
A settlement has been reached on the eve of trial in a class action against ANZ and OnePath alleging they slugged super fund members with excessive fees.
Fast food giant KFC has argued an initial trial in an underpayments class action could result in an “entirely hypothetical” finding unless it also deals with the claims of several sample group members.
A judge has made freezing orders against Melbourne developer City Built and director Robert Filippini, who allegedly received $160 million in investor funds from Keystone Asset Management.
A $100 million settlement by AMP in a class action by financial planners over the wealth manager’s buyer of last resort policy has been given the OK, but the litigation funder won’t be reimbursed for $2.6 million in insurance and administrative costs.
A contradictor appointed to represent group members’ interests in relation to a $100 million settlement in a class action against AMP wants to shave $2.6 million off the funder’s cut, telling the court that deductions for ATE insurance and administrative fees should not be approved.
Deciding an “unusually difficult” costs application, a judge has declined to award Monsanto all of its costs for defending a class action alleging its Roundup weed killer is carcinogenic, saying the agrochemical giant should have pushed harder for a split trial.
Plaintiff firm Maurice Blackburn will foot the bill for the unsuccessful class action against Monsanto over weed killer Roundup, but the company’s reluctance to split the trial in two has come back to bite it.